SHSusan Ha

Susan Ha

*This is an algorithmically generated author record based on publicly available information.

Susan Ha has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Figure S1 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    Chemical structures and IC50 of the multivalent ethisterone-peptoid conjugate

  • Open Access

    Figure S5 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    Model for MPC309 effect on AR-dependent gene expression

  • Open Access

    Figure S3 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    Effects of MPC309 versus ethisterone on gene expression in LNCaP-abl cells

  • Open Access

    Figure S4 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    PK of MPC309 and effects of MPC309 on immune cells

  • Open Access

    Supplementary Figure Legends from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    Figure legends for the supplemental data

  • Open Access

    Figure S2 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    Comparison of MPC309 antiproliferative activity in DU145, PC3, LNCaP and 22Rv1 and effects on AR-dependent gene expression

  • Open Access

    Data from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.

  • Open Access

    Data from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.

  • A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer

    by Justine Habault, Jeffrey A. Schneider, Susan Ha, Rachel Ruoff, Luiza D. Doro Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C. Kasper, et al.

    Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.


  • Open Access

    Expression of androgen receptor and its phosphorylated forms in breast cancer progression

    by Qinghu Ren, Liying Zhang, Rachel Ruoff, Susan Ha, Jinhua Wang, Shilpa Jain, Victor Reuter, William Gerald, Dilip D. Giri, Jonathan Melamed, et al.

    BACKGROUND: Androgen receptor (AR) expression in breast cancers may serve as a prognostic and predictive marker. We examined the expression pattern of AR and its phosphorylated forms, Ser‐213 (AR‐Ser[P]‐213) and Ser‐650 (AR‐Ser[P]‐650), in breast cancer and evaluated their association with clinicopathological parameters.METHODS: Immunohistochemistry was performed on primary and distant metastatic breast cancers and benign breast tissue using antibodies against AR, AR‐Ser(P)‐213, and AR‐Ser(P)‐650. The levels of cytoplasmic and nuclear expression were scored semiquantitatively using a histoscore.RESULTS: Nuclear staining of AR was observed in all benign breast tissue and 67% of cancer cases. Nuclear and cytoplasmic AR‐Ser(P)‐213 was increased in breast cancers 2‐fold (P = .0014) and 1.7‐fold (P = .05), respectively, compared with benign controls, whereas nuclear and cytoplasmic AR‐Ser(P)‐650 expression was decreased in tumors by 1.9‐fold and 1.7‐fold (both P < .0001), respectively. Increased expression of nuclear or cytoplasmic AR‐Ser(P)‐213 was observed in metastatic breast cancers (1.3‐fold, P = .05), ER‐negative (2.6‐fold, P = .001), and invasive ductal carcinoma (6.8‐fold, P = .04). AR‐Ser(P)‐650 expression was downregulated in lymph node‐positive breast cancers (1.4‐fold, P = .02) but was upregulated in invasive ductal carcinomas (3.2‐fold, P < .0001) and metastases (1.5‐fold, P = .003). Moreover, in ER‐negative breast cancers, nuclear AR‐Ser(P)‐650 was decreased (1.4‐fold, P = .005), and cytoplasmic AR‐Ser(P)‐650 was increased (1.4‐fold, P = .003).CONCLUSIONS: AR and its phosphorylation at serines 213 and 650 are differentially expressed in breast cancer tumorigenesis and progression. Phosphorylation of AR at serines 213 and 650 is increased in ER‐negative breast cancers, ductal carcinomas, and metastases and may have predictive value in breast cancer prognosis. Cancer 2013;119:2532–2540. © 2013 American Cancer Society.